| ORIGINAL ARTICLE |
|
| Year : 2020 | Volume
: 25
| Issue : 1 | Page : 25 |
|
|
TP53 rs1042522 polymorphism and early-onset breast cancer
Irmak Icen-Taskin1, Sevgi Irtegun-Kandemir2, Omer Munzuroglu3
1 Department of Molecular Biology and Genetics, Faculty of Science and Art, Inonu University, Malatya, Turkey
2 Department of Medical Biology, Faculty of Medicine, Dicle University, Diyarbakir, Turkey
3 Department of Bioengineering, Faculty of Engineering, Firat University, Elazig, Turkey
Correspondence Address:
Dr. Sevgi Irtegun-Kandemir
Department of Medical Biology, Faculty of Medicine, Dicle University, Diyarbakir 21280
Turkey
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/jrms.JRMS_506_19
|
|
|
Background: Breast cancer is the leading cause of cancer deaths among women. Early-onset breast cancer is well recognized as it clinically differs from old-age diagnosed breast neoplasms. TP53 rs1042522 polymorphism relates to the risk of breast neoplasms, but this relationship in Turkish early-onset breast cancer patients has not been investigated yet. We aimed to search the relationship between TP53 rs1042522 polymorphism and young Turkish breast cancer patients. Materials and Methods: Ninety-six female breast cancer patients who were ≤ 40 years of age and 96 healthy controls were enrolled in our study. Participants were genotyped by the hybridization probe system. Results: We identified that the genotype frequencies of rs1042522 were significantly different between controls and cases (P = 0.027). Participants carrying CG genotype had also reduced breast cancer risk (odds ratio = 0.4196, 95% confidence interval: 0.1941–0.9067, P= 0.027). Our results revealed that there is an association between GG and CG + CC genotype groups with progesterone receptor (PgR) status (P = 0.0219). Conclusion: Our findings indicate that the CG genotype is a protective factor against breast neoplasms. No other clinicopathologic parameters except for PgR status were found to be related to rs1042522 polymorphism in young Turkish breast cancer patients.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
